These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 35029952)
1. Guidelines for When to Consider Mortality-Reducing Treatments for Patients With Type 2 Diabetes Mellitus. Shaughnessy AF Am Fam Physician; 2022 Jan; 105(1):93. PubMed ID: 35029952 [No Abstract] [Full Text] [Related]
2. Risk factor reduction in type 2 diabetes demands a multifactorial approach. Rydén L; Ferrannini G; Mellbin L Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):81-91. PubMed ID: 31766912 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725 [TBL] [Abstract][Full Text] [Related]
4. Determining When to Recommend Glucose-Lowering Drugs That Reduce Cardiovascular Risk. Robertson S Am Fam Physician; 2022 Jan; 105(1):10-12. PubMed ID: 35029936 [No Abstract] [Full Text] [Related]
5. In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality. Kelsey MD; Newby LK Ann Intern Med; 2022 Mar; 175(3):JC26. PubMed ID: 35226528 [TBL] [Abstract][Full Text] [Related]
6. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918 [TBL] [Abstract][Full Text] [Related]
7. Cardiorenal protection of sodium-glucose cotransporter 2 inhibitors beyond diabetes: news from the European Society of Cardiology Congress 2020. Ferrannini G Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):341-342. PubMed ID: 32991694 [No Abstract] [Full Text] [Related]
13. Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020. Hirsch IB; Gaudiani LM JAMA; 2020 Jun; 323(23):2419-2420. PubMed ID: 32442246 [No Abstract] [Full Text] [Related]
14. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. Libianto R; Davis TM; Ekinci EI Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303 [TBL] [Abstract][Full Text] [Related]
15. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Gonzalez DE; Foresto RD; Ribeiro AB Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531 [TBL] [Abstract][Full Text] [Related]
16. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes. O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637 [TBL] [Abstract][Full Text] [Related]
17. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes. Ferraro RA; Nass CM; Dudum R; Blumenthal RS; Sarkar S Am J Med; 2019 Sep; 132(9):1027-1031. PubMed ID: 30904510 [TBL] [Abstract][Full Text] [Related]
18. Diabetes medications and cardiovascular disease: at long last progress. Lupsa BC; Inzucchi SE Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916 [TBL] [Abstract][Full Text] [Related]
19. A review on cardiovascular effects of newer hypoglycaemic medications. Cutshall BT; Twilla JD; Olinger AS; Oliphant CS Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743 [TBL] [Abstract][Full Text] [Related]